C12N 2750/14143
Viral genome or elements thereof as genetic vector
Official title: viral genome or elements thereof as genetic vector
C12N2750/14143 (Viral genome or elements thereof as genetic vector) appears on 2,655 US grants and 6,909 published applications in this corpus.
Search patents in C12N- Granted patents
- 2,655
- Published applications
- 6,909
- Assignees
- 1,495
- Inventors
- 8,925
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 2 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 3 | 0 |
| 1996 | 3 | 0 |
| 1997 | 12 | 0 |
| 1998 | 13 | 0 |
| 1999 | 21 | 0 |
| 2000 | 23 | 0 |
| 2001 | 30 | 10 |
| 2002 | 34 | 71 |
| 2003 | 24 | 72 |
| 2004 | 15 | 58 |
| 2005 | 20 | 60 |
| 2006 | 31 | 57 |
| 2007 | 22 | 50 |
| 2008 | 14 | 59 |
| 2009 | 23 | 53 |
| 2010 | 35 | 56 |
| 2011 | 23 | 50 |
| 2012 | 25 | 52 |
| 2013 | 25 | 76 |
| 2014 | 42 | 93 |
| 2015 | 52 | 105 |
| 2016 | 60 | 184 |
| 2017 | 76 | 194 |
| 2018 | 90 | 267 |
| 2019 | 119 | 375 |
| 2020 | 161 | 451 |
| 2021 | 212 | 594 |
| 2022 | 211 | 707 |
| 2023 | 258 | 737 |
| 2024 | 264 | 845 |
| 2025 | 379 | 939 |
| 2026 | 330 | 694 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods and materials for ameliorating creatine deficiency disorders6 Oct 2026US 12,751,995 B2The Regents of the University of California
- Engineered meganucleases having specificity for a recognition sequence in the hydroxyacid oxidase 1 gene6 Oct 2026US 12,752,019 B2Precision BioSciences, Inc.
- Microdystrophin nucleic acid gene therapy constructs and uses thereof6 Oct 2026US 12,752,020 B2REGENXBIO Inc.
- Methods of manufacturing microdystrophin gene therapy constructs6 Oct 2026US 12,752,021 B2REGENXBIO Inc.
- OPA1 antisense oligomers for treatment of conditions and diseases6 Oct 2026US 12,753,408 B2Stoke Therapeutics, Inc.
- Treating a type i interferon upregulation or aberrant il-33 upregulation disease or condition with polyomavirus8 Oct 2026US 2026/0306609 A1The General Hospital Corporation
- Capsids and methods of targeting neurons8 Oct 2026US 2026/0306661 A1Capsigen Inc.
- Molecular-genetic strategy for the reactivation of juvenile plasticity in targeted adult neural circuits8 Oct 2026US 2026/0306662 A1The Regents of the University of California
- Recombinant adeno-associated viral vectors for multipartite gene delivery and stargardt disease treatment8 Oct 2026US 2026/0306667 A1Abeona Therapeutics Inc.
- Methods of treating neurodegenerative disorders8 Oct 2026US 2026/0306669 A1
Most cited
By later US patents
- AAV transduction vectors618US 5,139,941 AUniversity of Florida Research Foundation, Inc. · 1992
- CRISPR-Cas component systems, methods and compositions for sequence manipulation560US 8,795,965 B2Massachusetts Institute of Technology · 2014
- CRISPR-Cas component systems, methods and compositions for sequence manipulation529US 8,871,445 B2Massachusetts Institute of Technology · 2014
- Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation489US 8,865,406 B2Massachusetts Institute of Technology · 2014
- Adeno-associated virus as eukaryotic expression vector481US 4,797,368 AThe United States of America as represented by the Department of Health and Human Services · 1989